For more information about the RetnaGene
™
tests, please call a myNicox concierge professional at
1.855.MY.NICOX (1.855.696.4269), email concierge@myNicox.com, or visit myNicox.com/RetnaGene.
No test is perfect. The RetnaGene
™
AMD and RetnaGene
™
LR laboratory-developed tests are highly accurate, genetic tests.
However, erroneous results may occur in rare cases.
The RetnaGene
™
AMD and RetnaGene
™
LR laboratory-developed tests were validated under federal laboratory guidelines
by Sequenom Center for Molecular Medicine, dba Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc.
The tests have not been cleared or approved by the US Food and Drug Administration (FDA). Although laboratory-developed
tests to date have not been subject to US FDA regulation, certication of the laboratory is required under CLIA to ensure the
quality and validity of the test. Sequenom Laboratories is CAP-accredited and CLIA-certied to perform high-complexity
clinical laboratory tests.
AMD=age-related macular degeneration; CAP=College of American Pathologists; CLIA=Clinical Laboratory
Improvement Amendments.
Sequenom and RetnaGene are trademarks of Sequenom, Inc. and are used
with permission by Sequenom Center for Molecular Medicine, LLC, dba
Sequenom Laboratories.
© 2014 Sequenom Laboratories. All rights reserved.
© 2014 Nicox, Inc. All rights reserved. www.nicox.com 31-31024R1.0 0614
Testing performed exclusively by:
RetnaGene
™
is a portfolio of laboratory-developed genetic tests that provides
a highly accurate and comprehensive risk assessment for advanced AMD.
Now, visionary science puts the power of prediction in your hands
Advanced Genotyping
Reveals Future AMD Risk
2-11 O&C_EW July 2014-DL_Layout 1 6/30/14 8:32 AM Page 5
